OnKure Therapeutics, Inc.
NGM: OKURLive Quote
📈 ZcoreAI Score
Our AI model analyzes OnKure Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get OKUR Z-Score →About OnKure Therapeutics, Inc.
Healthcare
Biotechnology
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
📊 Fundamental Analysis
OnKure Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -74.4%, which indicates that capital utilization is currently under pressure.
At a current price of $4.30, OKUR currently trades near the top of its 52-week range (85%) (Range: $1.70 - $4.75).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
Key Financials
Market Cap
$58.80M
Trailing P/E
--
Forward P/E
-2.09
Beta (5Y)
--
52W High
$4.75
52W Low
$1.70
Avg Volume
283K
Day High
Day Low